As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.
Med (New York, N.Y.). 2024 Mar 08 [Epub]
Kriti Mittal, Monika Joshi
University of Massachusetts Medical Center, Worcester, MA, USA., Penn State Cancer Institute, Hershey, PA, USA. Electronic address: .